Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 1
2004 3
2005 3
2006 2
2007 2
2008 8
2009 7
2010 3
2011 5
2012 1
2013 2
2016 1
2018 1
2019 2
2020 3
2021 3
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

58 results

Results by year

Filters applied: . Clear all
Page 1
Yoga Programme for Type 2 Diabetes Prevention (YOGA-DP): A Qualitative Study Exploring the Trial Team's Facilitators and Challenges in Conducting a Feasibility Trial in India.
Mishra P, Greenfield SM, Harris T, Hamer M, Lewis SA, Singh K, Nair R, Mukherjee S, Tandon N, Kinra S, Manjunath NK, Prabhakaran D, Chattopadhyay K. Mishra P, et al. Diabetes Ther. 2023 Oct;14(10):1695-1709. doi: 10.1007/s13300-023-01450-0. Epub 2023 Aug 10. Diabetes Ther. 2023. PMID: 37561266 Free PMC article.
Correction to: Yoga Programme for Type 2 Diabetes Prevention (YOGA-DP) Among High-Risk People in India: A Multicenter Feasibility Randomized Controlled Trial.
Chattopadhyay K, Mishra P, Singh K, Singh K, Harris T, Hamer M, Greenfield SM, Manjunath NK, Nair R, Mukherjee S, Tandon N, Lewis SA, Kinra S, Prabhakaran D; YOGA-DP Study Team. Chattopadhyay K, et al. Diabetes Ther. 2023 Jul;14(7):1155-1156. doi: 10.1007/s13300-023-01420-6. Diabetes Ther. 2023. PMID: 37223849 Free PMC article. No abstract available.
Yoga Programme for Type 2 Diabetes Prevention (YOGA-DP) Among High-Risk People in India: A Multicenter Feasibility Randomized Controlled Trial.
Chattopadhyay K, Mishra P, Singh K, Singh K, Harris T, Hamer M, Greenfield SM, Manjunath NK, Nair R, Mukherjee S, Tandon N, Lewis SA, Kinra S, Prabhakaran D; YOGA-DP Study Team. Chattopadhyay K, et al. Diabetes Ther. 2023 Jul;14(7):1137-1154. doi: 10.1007/s13300-023-01395-4. Epub 2023 Mar 31. Diabetes Ther. 2023. PMID: 37002475 Free PMC article.
A clinical guideline-based management of type 2 diabetes by ayurvedic practitioners in Nepal: A feasibility cluster randomized controlled trial protocol.
Chattopadhyay K, Dhimal M, Karki S, Regmi P, Bista B, Biswas TK, Heinrich M, Panniyammakal J, Tandon N, Leonardi-Bee J, Kinra S, Greenfield SM, Lewis SA, Upadhyay V, Gyanwali P. Chattopadhyay K, et al. Medicine (Baltimore). 2022 Nov 25;101(47):e31452. doi: 10.1097/MD.0000000000031452. Medicine (Baltimore). 2022. PMID: 36451377 Free PMC article.
Effectiveness and Safety of Ayurvedic Medicines in Type 2 Diabetes Mellitus Management: A Systematic Review and Meta-Analysis.
Chattopadhyay K, Wang H, Kaur J, Nalbant G, Almaqhawi A, Kundakci B, Panniyammakal J, Heinrich M, Lewis SA, Greenfield SM, Tandon N, Biswas TK, Kinra S, Leonardi-Bee J. Chattopadhyay K, et al. Front Pharmacol. 2022 Jun 8;13:821810. doi: 10.3389/fphar.2022.821810. eCollection 2022. Front Pharmacol. 2022. PMID: 35754481 Free PMC article.
Feasibility Trial of Yoga Programme for Type 2 Diabetes Prevention (YOGA-DP) among High-Risk People in India: A Qualitative Study to Explore Participants' Trial- and Intervention-Related Barriers and Facilitators.
Mishra P, Harris T, Greenfield SM, Hamer M, Lewis SA, Singh K, Nair R, Mukherjee S, Manjunath NK, Tandon N, Kinra S, Prabhakaran D, Chattopadhyay K. Mishra P, et al. Int J Environ Res Public Health. 2022 May 1;19(9):5514. doi: 10.3390/ijerph19095514. Int J Environ Res Public Health. 2022. PMID: 35564908 Free PMC article. Clinical Trial.
Yoga Program for Type 2 Diabetes Prevention (YOGA-DP) Among High-Risk People: Qualitative Study to Explore Reasons for Non-participation in a Feasibility Randomized Controlled Trial in India.
Mishra P, Greenfield SM, Harris T, Hamer M, Lewis SA, Singh K, Nair R, Mukherjee S, Krishnamurthy Manjunath N, Harper DR, Tandon N, Kinra S, Prabhakaran D, Chattopadhyay K. Mishra P, et al. Front Public Health. 2021 Sep 3;9:682203. doi: 10.3389/fpubh.2021.682203. eCollection 2021. Front Public Health. 2021. PMID: 34540780 Free PMC article. Clinical Trial.
Inositol-Requiring Enzyme 1α-Mediated Synthesis of Monounsaturated Fatty Acids as a Driver of B Cell Differentiation and Lupus-like Autoimmune Disease.
Zhang Y, Gui M, Wang Y, Mani N, Chaudhuri S, Gao B, Li H, Kanwar YS, Lewis SA, Dumas SN, Ntambi JM, Zhang K, Fang D. Zhang Y, et al. Among authors: lewis sa. Arthritis Rheumatol. 2021 Dec;73(12):2314-2326. doi: 10.1002/art.41883. Epub 2021 Nov 2. Arthritis Rheumatol. 2021. PMID: 34105254 Free PMC article.
58 results